论文期刊

取消

高级检索

检索历史清除

首页> Cancer chemotherapy and pharmacology> A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.

A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.

导出原文传递

翻译打印收藏纠错

作者： C,Massard ^[1] ; P A,Cassier ^[2] ; A,Azaro ^[3] ; B,Anderson ^[4] ; E,Yuen ^[5] ; D,Yu ^[5] ; G,Oakley ^[5] ; K A,Benhadji ^[5] ; S,Pant ^[6]

作者单位： Drug Development Department (DITEP), Inserm Unit U981, Universite´ Paris Saclay, Universite´ Paris-Sud, Gustave Roussy, Villejuif, France. Christophe.Massard@gustaveroussy.fr. ^[1] Department of Medicinal Oncology, Centre Léon Bérard, Lyon, France. ^[2] Molecular Therapeutics Research Unit, Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. ^[3] Department of Pharmacology, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. ^[4] Eli Lilly and Company, Indianapolis, IN, USA. ^[5] Eli Lilly and Company, New York, NY, USA. ^[6] Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas Medical Center/MD Anderson Cancer Center, Houston, TX, USA. ^[7]

关键词 Crenigacestat LY3039478 Metastatic cancer Notch inhibition

主题词抗肿瘤药(Antineoplastic Agents);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);苯丙氮|艹卓|类(Benzazepines);卡铂(Carboplatin);顺铂(Cisplatin);脱氧胞苷(Deoxycytidine);人类(Humans);肿瘤(Neoplasms);肿瘤, 继发原发性(Neoplasms, Second Primary)

DOI 10.1007/s00280-022-04461-z

PMID 36030462

发布时间 2022-12-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Cancer chemotherapy and pharmacology

Cancer chemotherapy and pharmacology

2022年90卷4期

335-344页

相似文献

中文期刊
外文期刊
学位论文
会议论文

特别提示：本网站仅提供医学学术资源服务，不销售任何药品和器械，有关药品和器械的销售信息，请查阅其他网站。

客服热线：4000-115-888 转3 (周一至周五：8:00至17:00)
|
客服邮箱：yiyao@wanfangdata.com.cn

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

官方微信

万方医学小程序

关于我们网站地图知识产权

北京万方数据股份有限公司

万方数据电子出版社

京ICP证010071号

京公网安备11010802020237号

京ICP备08100800号-1

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

new翻译充值订阅收藏移动端

官方微信

万方医学小程序

调查问卷